Shire Targets Fourth Quarter Filing of BLA for REPLAGAL
ConjuChem Announces Fiscal 2009 Third Quarter Financial Results
To keep up to date with news from this category use our ![]()
Norgine acquires cetilistat
October 26, 2009 -- Norgine BV today announced that it has purchased cetilistat, a novel treatment for obesity from Alizyme Therapeutics Limited. Norgine has acquired global rights to the product, including an...
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin...
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...
Shire Targets Fourth Quarter Filing of BLA for REPLAGAL
Massachusetts - 21 Oct 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration...
ConjuChem Announces Fiscal 2009 Third Quarter Financial Results
MONTREAL, Canada, September 14, 2009 - ConjuChem Biotechnologies (TSX:CJB) today announced financial results for the third quarter of fiscal 2009, ended July 31, 2009. "During our fiscal third quarter, we had the...